2. Cell Cycle/DNA Damage Epigenetics Stem Cell/Wnt JAK/STAT Signaling Immunology/Inflammation
  3. PARP STAT STING IFNAR
  4. KMR-206

KMR-206 is a PARP7 inhibitor with an IC50 of 13.7 nM. KMR-206 relieves AHR-mediated transcriptional repression and enhances CYP1A1 expression in the presence of TCDD. KMR-206 induces the STING-dependent IFN-β signaling pathway and increases the levels of STAT1, pSTAT1 and nuclear PARP7 in cancer cells. KMR-206 reduces the viability of lung adenocarcinoma cells, enhances radiation-induced immunogenic signals, and induces the production of immunogenic signals in glioblastoma cancer stem cells. KMR-206 destabilizes FRA1 to increase IRF1 levels and promotes the IRF3-CBP/p300 interaction. KMR-206 can be used in studies related to lung adenocarcinoma and glioblastoma.

For research use only. We do not sell to patients.

KMR-206

KMR-206 Chemical Structure

CAS No. : 2992741-10-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

KMR-206 Related Antibodies

Top Publications Citing Use of Products

View All PARP Isoform Specific Products:

View All Isoforms
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KMR-206 is a PARP7 inhibitor with an IC50 of 13.7 nM. KMR-206 relieves AHR-mediated transcriptional repression and enhances CYP1A1 expression in the presence of TCDD. KMR-206 induces the STING-dependent IFN-β signaling pathway and increases the levels of STAT1, pSTAT1 and nuclear PARP7 in cancer cells. KMR-206 reduces the viability of lung adenocarcinoma cells, enhances radiation-induced immunogenic signals, and induces the production of immunogenic signals in glioblastoma cancer stem cells. KMR-206 destabilizes FRA1 to increase IRF1 levels and promotes the IRF3-CBP/p300 interaction. KMR-206 can be used in studies related to lung adenocarcinoma and glioblastoma[1][2].

IC50 & Target

PARP7

13.7 nM (IC50)

STAT1

 

IFNAR1

 

In Vitro

KMR-206 potently and selectively inhibits the catalytic activity of purified PARP7 in vitro, with an IC50 of 13.7 nM[1].
KMR-206 (0.001-0.3 μM; duration sufficient to measure MARylation) inhibits the auto-MARylation of GFP-PARP7 in HEK 293T cells with an EC50 of 8 nM, and upregulates GFP-PARP7 protein levels in a dose-dependent manner[1].
KMR-206 (0.1-1000 nM; 24 h) reverses AHR ligand-mediated transcriptional inhibition of CYP1A1 in WT MEFs in a dose-dependent manner in vitro, with a saturating effect observed at 100 nM[1].
KMR-206 (100 nM; 24 h) increases the IFN-β mRNA level in WT MEFs[1].
KMR-206 (0.01-0.3 μM; 16 h) dose-dependently induces the IFN-β signaling pathway in CT-26 cells, including upregulating STAT1/pSTAT1 levels, STING-dependent IFN-β secretion, and ISRE reporter gene activity[1].
KMR-206 (0.01-0.3 μM; 16 h) upregulates the endogenous PARP7 protein level in CT-26 cells in a dose-dependent manner[1].
KMR-206 (6 days) reduces the viability of NCI-H1373 cells in a dose-dependent manner with an EC50 of 104 nM, but exerts no effect on the viability of CT-26 cells[1].
KMR-206 (300 nM; imaged at 0, 30, 120 min post-treatment) alters the nuclear localization of GFP-PARP7 in HeLa cells, converting punctate nuclear localization into a diffuse pan-nuclear pattern within 30 min post-treatment[1].
KMR-206 (300 nM; added 2 h prior to irradiation and removed 24 h after irradiation) sensitizes human glioblastoma cell lines U251, T98G and KALS-1 to X-ray irradiation[2].
KMR-206 (administered 2 h before the first radiation fraction and maintained for 72 h after the last fraction) enhances radiotherapy-induced IFN-I and pro-inflammatory gene expression in U251, T98G and KALS-1 human glioblastoma cell lines, and exerts cell line-specific effects on gene targets and pathway enrichment[2].
KMR-206 (300 nM; added 2 h prior to irradiation and maintained for 72 h after irradiation) enhances radiation-induced activation of the IFN-I pathway in T98G cells and also enhances IFN-I pathway activation in KALS-1 cells[2].
Supernatants generated from the combined treatment of human glioblastoma cell lines U251, T98G and KALS-1 with KMR-206 (300 nM; added 2 h prior to the first radiation fraction and maintained for 72 h after the last fraction) and 3 × 8 Gy X-rays activate primary human NK, NKT and monocyte populations, with cell line-specific activation characteristics[2].
Combination of KMR-206 (administered 2 h before the first radiotherapy fraction and maintained for 72 h after the last fraction) with X-ray irradiation induces activation of the IFN-I pathway and expression of proinflammatory cytokines in STING-low-expressing LK17 patient-derived human glioblastoma cancer stem cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KMR-206 Related Antibodies

Western Blot Analysis[1]

Cell Line: HEK 293T cells expressing GFP-PARP7
Concentration: 0.001, 0.01, 0.03, 0.1, 0.3 μM
Incubation Time: duration sufficient to measure MARylation
Result: Induced a dose-dependent decrease in GFP-PARP7 auto-MARylation with an EC50 of 8 nM.
Caused a dose-dependent increase in GFP-PARP7 protein levels.

Real Time qPCR[1]

Cell Line: WT mouse embryonic fibroblasts (MEFs)
Concentration: 100 nM
Incubation Time: 24 h (alone); 4 h (with 100 ng/mL 3pRNA or 5 μg/mL cGAMP)
Result: Induced a 3-fold increase in IFN-β mRNA when used alone.
Caused a synergistic induction of IFN-β mRNA when co-treated with 3pRNA or cGAMP, with drastically higher levels than either treatment alone.
Molecular Weight

506.53

Formula

C29H23FN6O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

N#CC1=CC=C(N2CCN(C(C3=CC(CC4=NNC(C5=C4C=C(C#CC)C=C5)=O)=CC=C3F)=O)CC2)N=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (98.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9742 mL 9.8711 mL 19.7422 mL
5 mM 0.3948 mL 1.9742 mL 3.9484 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9742 mL 9.8711 mL 19.7422 mL 49.3554 mL
5 mM 0.3948 mL 1.9742 mL 3.9484 mL 9.8711 mL
10 mM 0.1974 mL 0.9871 mL 1.9742 mL 4.9355 mL
15 mM 0.1316 mL 0.6581 mL 1.3161 mL 3.2904 mL
20 mM 0.0987 mL 0.4936 mL 0.9871 mL 2.4678 mL
25 mM 0.0790 mL 0.3948 mL 0.7897 mL 1.9742 mL
30 mM 0.0658 mL 0.3290 mL 0.6581 mL 1.6452 mL
40 mM 0.0494 mL 0.2468 mL 0.4936 mL 1.2339 mL
50 mM 0.0395 mL 0.1974 mL 0.3948 mL 0.9871 mL
60 mM 0.0329 mL 0.1645 mL 0.3290 mL 0.8226 mL
80 mM 0.0247 mL 0.1234 mL 0.2468 mL 0.6169 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KMR-206 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KMR-2062992741-10-1KMR206KMR 206PARPSTATSTINGIFNARpoly ADP ribose polymerase Stimulator of Interferon GenesTMEM173MITAERISMPYSInterferon-α/β receptorInterferon-alpha/beta receptorRIG-ICYP1A1lung adenocarcinomaPARP7NAD+IFN-βHEK 293T cellsAHRglioblastoma cancer stem cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KMR-206
Cat. No.:
HY-17663
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.